<style face="normal" font="default" size="100%">Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study</style>

Drupal-Biblio